Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9787)	12/17/2003 3:16:47 PM
From: Sam Citron	Read Replies (1) \| Respond to of 52153

Peter, I'm quite serious about this. How many biotechs that you know of have CEOs who are MBAs? I don't think there are too many -- Kevin Sharer at Amgen being one of the outstanding exceptions. Wyeth's CEO, Robert Essner, is no MBA either, BTW. I am not one who thinks that there is an underrepresentation of MBAs in the executive ranks of American businesses in general. Nor do I believe that the degree guarantees value. However, it occurs to me that it is especially important for biotechs and pharmas of a certain size to run the business as a portfolio and that of all degrees MBAs may be most predisposed to doing so. Sam